Retatrutide vs Semaglutide
Triple agonist vs GLP-1 single agonist — what the clinical data shows and what it does not.
Retatrutide and semaglutide (Ozempic/Wegovy) are both injectable GLP-1 receptor agonists, but they differ substantially in mechanism, evidence base, and regulatory status. This comparison draws on published Phase 2 data for retatrutide (Jastreboff et al., NEJM 2023) and Phase 3 data for semaglutide (STEP 1, STEP 2, SELECT). No direct head-to-head randomized controlled trial has been published. All cross-trial comparisons have important limitations.
Mechanism of Action — Where They Differ
Both drugs activate the GLP-1 receptor, which suppresses appetite, slows gastric emptying, and stimulates glucose-dependent insulin secretion. Semaglutide is a selective GLP-1 receptor agonist — that is its only mechanism. Retatrutide adds two additional receptor targets: GIP (glucose-dependent insulinotropic polypeptide) and glucagon. GIP receptor agonism is thought to enhance the weight-loss effect of GLP-1 agonism and may improve tolerability. Glucagon receptor agonism increases energy expenditure and promotes fat oxidation in the liver — a mechanism not present in semaglutide. This triple-receptor engagement is the primary reason retatrutide produces greater weight loss in Phase 2 and Phase 3 data, and also why its heart rate increase is larger.
15-Point Clinical Comparison
Cross-trial comparisons are inherently limited by differences in study populations, protocols, endpoints, and follow-up duration. No head-to-head randomized controlled trial of retatrutide vs semaglutide has been published. Data sourced from Jastreboff et al. (NEJM 2023) for retatrutide Phase 2 and Wilding et al. (NEJM 2021, STEP 1) for semaglutide Phase 3.
Weight Loss Data — What the Trials Show
Retatrutide Phase 2 (NEJM 2023, 48 weeks, 12 mg, n=338): mean body weight reduction of ~24.2%. Phase 3 TRIUMPH-1 topline (announced May 21, 2026, 80 weeks, 12 mg): mean body weight reduction of ~28.3% — the largest weight loss reported in any Phase 3 obesity drug trial to date. These are separate studies: the Phase 2 figure is from the published NEJM paper; the 28.3% figure is from the Phase 3 TRIUMPH-1 topline announcement, not from the Phase 2 extended follow-up. Semaglutide Phase 3 STEP 1 (68 weeks, 2.4 mg, n=1961): mean body weight reduction of ~14.9%. STEP 4 (continued treatment): ~17.4% at 68 weeks. These are not head-to-head results. TRIUMPH-1 and TRIUMPH-2 topline results have been reported; peer-reviewed publications are pending.
Side Effects — Similarities and Key Differences
Both drugs share the GLP-1 agonist class side effect profile: nausea, vomiting, diarrhea, and constipation are the most common adverse events for both. The key differences are in magnitude and in heart rate. Retatrutide at 12 mg produced nausea in ~45% of participants vs ~20% for semaglutide 2.4 mg (STEP 1). Discontinuation due to adverse events was ~16% at 12 mg for retatrutide vs ~7% for semaglutide. Retatrutide also produces a larger resting heart rate increase (+4–7 bpm at 12 mg vs +1–3 bpm for semaglutide), likely due to glucagon receptor agonism. Both carry the same class-level thyroid C-cell tumor precaution based on rodent data.
Cardiovascular Outcomes — A Critical Difference
Semaglutide has published cardiovascular outcomes trial data. SELECT (2023) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in adults with obesity and established cardiovascular disease — a landmark result that expanded semaglutide's clinical profile beyond weight loss. SUSTAIN-6 showed similar CV benefits in type 2 diabetes. Retatrutide has no published CVOT data. TRIUMPH-Outcomes is an ongoing Phase 3 cardiovascular outcomes trial, but results are not expected before 2027–2028. This is a meaningful evidence gap: clinicians treating patients with obesity and cardiovascular disease have established data for semaglutide and none for retatrutide.
Liver Disease (MASH/MASLD) Data
Semaglutide has Phase 2 MASH data (NASH trial, 2021): 59% of participants achieved NASH resolution vs 17% placebo. Phase 3 ESSENCE trial is ongoing. Retatrutide has Phase 2 data showing significant reductions in liver fat (MRI-PDFF) and liver enzymes, consistent with its glucagon receptor agonism, which promotes hepatic fat oxidation. Phase 3 TRIUMPH-MASH is ongoing. Neither drug has an approved MASH indication as of September 2026.
Muscle Mass and Body Composition
Rapid weight loss with any agent can result in lean mass reduction. Phase 3 TRIUMPH trials include body composition endpoints for retatrutide. Semaglutide Phase 3 data (STEP 1) showed that approximately 39% of weight lost was lean mass — a finding that has driven interest in combining GLP-1 agonists with resistance training and adequate protein intake. Retatrutide Phase 3 body composition data are pending. Current evidence suggests that adequate protein intake (≥1.2 g/kg ideal body weight/day) and resistance exercise substantially mitigate lean mass loss during GLP-1 agonist treatment regardless of which agent is used.
Access and Availability
Semaglutide (Wegovy for obesity, Ozempic for type 2 diabetes) is FDA-approved and commercially available by prescription in the United States. It has been subject to supply shortages but is generally accessible through licensed prescribers. Retatrutide is investigational and not commercially available. It can only be accessed through enrollment in an authorized clinical trial. Compounding of retatrutide is not legally permissible under current federal law. Anyone claiming to sell or provide retatrutide outside of an authorized trial is operating outside the law.
Common Questions
Is retatrutide better than Wegovy?
Phase 2 data suggests retatrutide may produce greater weight loss than semaglutide (Wegovy) — ~24% vs ~15% at comparable timepoints — but no direct head-to-head trial exists. Semaglutide is FDA-approved and commercially available today; retatrutide is investigational and only available in clinical trials. Comparing across different trials has significant limitations including different populations, durations, and protocols.
Is retatrutide a GLP-1 like semaglutide?
Yes — retatrutide activates the GLP-1 receptor like semaglutide, but it also activates the GIP and glucagon receptors simultaneously. This triple-receptor mechanism is hypothesized to produce greater metabolic effects than GLP-1 single agonism alone. The glucagon receptor component in particular is thought to increase energy expenditure and promote hepatic fat oxidation.
Can you take retatrutide instead of Ozempic?
No. Retatrutide is not FDA-approved and is not available by prescription. It is only available to participants enrolled in authorized clinical trials. Ozempic (semaglutide) is FDA-approved for type 2 diabetes and can be prescribed by a licensed physician. Anyone considering switching medications should consult their physician.
What is the difference between retatrutide and semaglutide?
Semaglutide activates only the GLP-1 receptor. Retatrutide activates three receptors: GLP-1, GIP, and glucagon. The additional GIP and glucagon receptor activation is hypothesized to produce greater weight loss and metabolic effects. Semaglutide is FDA-approved with extensive Phase 3 data including cardiovascular outcomes; retatrutide is investigational with Phase 2 data and ongoing Phase 3 trials.
Does retatrutide have more side effects than semaglutide?
At the highest doses, retatrutide appears to have a higher rate of GI adverse events (~45% nausea at 12 mg vs ~20% for semaglutide 2.4 mg) and a higher discontinuation rate (~16% vs ~7%). It also produces a larger resting heart rate increase (+4–7 bpm vs +1–3 bpm). Both drugs share the same class-level GI side effect profile and thyroid C-cell tumor precaution. Cross-trial comparisons have important limitations.
Does semaglutide have better cardiovascular data than retatrutide?
Yes — significantly. Semaglutide's SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in adults with obesity and established cardiovascular disease. This is a landmark result with no equivalent for retatrutide. TRIUMPH-Outcomes is evaluating retatrutide's cardiovascular safety, but results are not expected before 2027–2028. For patients with obesity and cardiovascular disease, semaglutide currently has a much stronger evidence base.
Why does retatrutide cause more nausea than semaglutide?
The higher GI adverse event rate with retatrutide at the highest doses is likely multifactorial: the greater absolute weight loss achieved (which correlates with GI effects), the higher dose levels tested, and potentially the additive effects of triple-receptor agonism. The TRIUMPH Phase 3 protocol uses slow dose escalation (4-week intervals) as the primary mitigation strategy. Most GI effects improve at stable maintenance dose.
Is retatrutide available as a compounded drug like semaglutide was?
No. Semaglutide was legally compounded during FDA-recognized shortage periods under specific conditions. Retatrutide has no approved NDA and does not currently satisfy federal requirements for bulk drug substance compounding under 503A or 503B. Any vendor claiming to sell compounded retatrutide is operating outside the law. See the Compounding page for the full legal analysis.
Evaluating Your Options?
A licensed physician can review your health history and help you understand which treatment options are appropriate for your situation.
Start Physician ReviewTryTrutide is an independent educational platform. This comparison is for informational purposes only and does not constitute medical advice. Retatrutide is investigational and not approved for any indication. Semaglutide is FDA-approved; consult a licensed physician before starting, stopping, or changing any medication. All weight loss figures are from published clinical trials and represent mean results — individual outcomes vary.